Business Paid
Molecure gets approval for Phase II trials for treatment of pulmonary sarcoidosis
00:57
Molecure S.A., a biotech firm, secured approvals from Danish, French, Greek, German, and Norwegian regulators to commence Phase II clinical trials for OATD-01, a novel CHIT1 inhibitor for pulmonary sarcoidosis.
This article is for subscribers
Warsaw Business Journal subscribers get the full archive (12,248 articles going back to 1995) and the print edition.
SubscribeOr try Poland A.M. free for 7 days, the daily briefing, or see all plans and prices.
